Clinicopathological Factors Associated with Gastric Signet Ring Cell Carcinoma in CDH1 Pathogenic Variant Carriers: Report from the GASTRIC Consortium

This study from the GASTRIC consortium identifies that while the absence of endoscopic findings is reassuring for CDH1 carriers, the presence of specific abnormalities like masses or signet ring cell foci are independent predictors of advanced gastric cancer, suggesting endoscopic surveillance may be a viable alternative to prophylactic gastrectomy for those without worrisome mucosal findings.

The Gist

The Big Picture: The "Silent Invader" and the "Master Key"

Imagine your body is a massive, bustling city. Inside this city, there are special "Master Keys" (genes) that tell the cells how to hold hands and stay in their proper neighborhoods. One of these keys is called CDH1.

In some families, this Master Key is broken (a "pathogenic variant"). When the key is broken, the cells in the stomach stop holding hands. Instead of staying in a neat row, they drift apart and turn into a sneaky, invisible enemy called Signet Ring Cell Carcinoma (SRCC).

The problem? This enemy is a master of disguise. It often hides so well that standard cameras (endoscopies) can't see it. For years, doctors have faced a tough choice:

1. The "Scorched Earth" Policy: Remove the whole stomach (gastrectomy) just in case the enemy is there, even if you can't see it.
2. The "Watchful Waiting" Policy: Keep checking with the camera, hoping to catch the enemy early before it grows too big.

This study, led by a huge team of doctors called the GASTRIC Consortium, wanted to figure out: How can we tell the difference between a stomach that just needs watching and one that needs to be removed immediately?

---

The Detective Work: What They Found

The researchers looked at 390 people with the broken CDH1 key from 12 different medical centers. They acted like detectives, comparing people who had cancer to those who didn't, and looking for clues.

1. The "Smoke and Mirrors" of the Stomach

When the doctors looked inside the stomachs with their cameras, they found that the "invisible" cancer often leaves behind subtle clues, like smoke before a fire.

• The Clues: If the stomach lining looked thickened, had bumps (nodules), or looked like a lump (mass), it was a strong warning sign.
• The Red Herring: Sometimes the stomach looked red or inflamed (gastritis), but that actually made it less likely to be the sneaky cancer. It was like seeing a messy room and assuming it's just a teenager's room, not a crime scene.

2. The "Goldilocks" Test: Sensitivity vs. Specificity

The study tried to find the perfect test to predict if the cancer had spread deep into the stomach wall (Advanced Disease). They found that different clues worked differently:

• The "Can't Miss" Clue (High Sensitivity): Finding the actual cancer cells on a biopsy was the best way to catch most of the bad cases. But, finding them didn't always mean the cancer was deep and dangerous. It was like hearing a loud noise; you know something is happening, but you don't know if it's a fire or just a dropped pan.
• The "Dead Giveaway" Clue (High Specificity): Seeing a mass or thickened folds was a very strong sign that the cancer was deep and dangerous. If you saw these, it was almost certainly a serious problem. However, these signs were rare; you wouldn't see them in every case.

The Big Takeaway:

• If the camera sees nothing weird: You can breathe a huge sigh of relief. The study found that if the stomach looked normal, it was almost 100% safe to keep watching and avoid surgery.
• If the camera sees something weird: It's a warning to talk to a surgeon, but it doesn't guarantee the cancer is advanced. It's like seeing a storm cloud; you need to prepare, but it might just be a light rain.

3. The "Surveillance" Success Story

The study followed people who chose to keep their stomachs and just get checked regularly (surveillance).

• The Good News: None of the people who were carefully watched and had no visible abnormalities developed advanced cancer.
• The Bad News: The few people who did get advanced cancer almost all had visible warning signs (like lumps or thickening) on their very first camera check.

The "So What?" for Patients

Think of the stomach as a house.

• The Old Rule: "If you have the broken key, tear the whole house down immediately, just in case there's a ghost."
• The New Rule (Based on this study): "If you have the broken key, check the house. If the walls look smooth and clean, you can stay and keep checking. If you see a crack in the wall or a weird bump, then we talk about tearing it down."

The Bottom Line

This study gives hope to people with the CDH1 mutation. It suggests that surgery isn't the only answer for everyone.

• No scary signs? You are likely safe to keep an eye on things.
• Scary signs? You need to have a serious conversation about surgery, because that's where the danger usually hides.

The researchers admit they need to keep watching these patients for a longer time to be 100% sure, but this is a massive step toward making the decision less scary and more personalized. It's about finding the right balance between being safe and keeping your body intact.

Technical Summary

1. Problem Statement

• Clinical Challenge: Individuals with pathogenic variants in the CDH1 gene (associated with Hereditary Diffuse Gastric Cancer) face a high lifetime risk of developing diffuse gastric cancer, specifically Signet Ring Cell Carcinoma (SRCC).
• Current Dilemma: The standard of care has historically been prophylactic total gastrectomy (TG) due to the difficulty of detecting early, localized (T1a) SRCC lesions endoscopically. However, penetrance is variable; many carriers harbor indolent T1a lesions that may never progress, while a subset develops advanced (>T1a) disease with poor outcomes.
• Knowledge Gap: There are no well-defined clinical, endoscopic, or pathological predictors to distinguish between carriers who will develop advanced cancer versus those with localized or no disease. This lack of risk stratification makes shared decision-making regarding surgery versus endoscopic surveillance difficult.

2. Methodology

• Study Design: Retrospective observational cohort study (1998–2025).
• Population: 390 CDH1 pathogenic/likely pathogenic variant carriers from 235 families across 12 academic centers in the US and Canada (Group of investigAtors STriving toward Research In CDH1 [GASTRIC] consortium).
• Data Collection:
  • Clinical: Demographics, family history, PPI use, smoking/alcohol status.
  • Endoscopic: Review of Esophagogastroduodenoscopy (EGD) reports (baseline and surveillance) for mucosal abnormalities (thickened folds, nodularity, masses, erythema, etc.) and biopsy results (random vs. targeted).
  • Pathological: Review of gastrectomy (TG) specimens for SRCC foci, depth of invasion (T1a vs. >T1a), and tumor size.
• Statistical Analysis:
  • GEE (Generalized Estimating Equations): Used to analyze repeated measures from multiple endoscopies per patient, accounting for within-patient correlation.
  • Comparative Tests: Mann-Whitney (continuous), Chi-square/Fisher's exact (categorical).
  • Multivariate Analysis: Logistic regression to identify independent predictors of advanced disease.
  • Performance Metrics: Sensitivity, Specificity, Positive Predictive Value (PPV), and Negative Predictive Value (NPV) calculated for endoscopic features predicting advanced cancer.
  • Note: No adjustment for multiple comparisons was made due to the rarity of the condition and advanced cases, prioritizing effect sizes and clinical relevance over strict p-value thresholds.

3. Key Contributions

• Largest Cohort to Date: This is the largest multi-center study of CDH1 carriers reported, with a specific focus on a significantly larger number of advanced cancer cases (n=11) compared to previous single-center reports (typically n=1–2).
• Risk Stratification Data: Provides the first robust data on the diagnostic performance of specific endoscopic and histologic features in predicting advanced-stage disease.
• Surveillance vs. Surgery Evidence: Offers evidence supporting the safety of endoscopic surveillance in carriers without specific high-risk mucosal findings, challenging the "one-size-fits-all" approach to prophylactic gastrectomy.

4. Key Results

A. Patient Characteristics

• Median age at diagnosis: 44.6 years.
• 52.4% (196/390) underwent total gastrectomy (TG).
• 90.6% underwent at least one EGD.

B. Predictors of SRCC Presence on Endoscopy

• Significant Associations: The presence of SRCC foci on biopsy was significantly associated with:
  • Endoscopic: Thickened mucosal folds, nodularity, masses, pale spots, and erythema.
  • Histologic: Gastric Intestinal Metaplasia (GIM).
  • Inverse Association: Gastritis (presence of gastritis reduced the likelihood of SRCC detection).
• Non-Associations: Age, sex, smoking, alcohol, PPI use, and H. pylori status were not associated with SRCC detection.

C. Predictors of Advanced Disease (>T1a)

• Incidence: Among those undergoing TG, 5.6% (11/196) had advanced disease.
• Endoscopic Findings: 90.9% of advanced cases had visible endoscopic abnormalities (masses, thickened folds, nodularity, etc.). The single case without findings was a post-gastric bypass patient.
• Multivariate Predictors:
  • Gastric Masses: Highly specific (0.99) but low sensitivity (0.18).
  • SRCC Foci on Baseline EGD: Most sensitive feature (0.81) but moderate specificity (0.74).
  • Thickened Folds: Highly specific (0.96) but low sensitivity (0.36).
• Predictive Values:
  • Negative Predictive Value (NPV): Consistently high (0.94–1.0). Absence of findings strongly rules out advanced disease.
  • Positive Predictive Value (PPV): Generally modest (0.13–0.21), except for masses (0.66) and thickened folds (0.40). Presence of findings does not reliably confirm advanced disease.

D. Oncologic Outcomes

• Advanced Cases: 4 of the 11 patients with advanced disease died of cancer complications. All 4 had visible lesions on their index EGD; 2 presented with symptoms (pain or bleeding).
• Surveillance Cohort: No carriers in the surveillance group (those who did not undergo immediate TG) developed advanced cancer or died of gastric cancer during the follow-up period.

5. Significance and Clinical Implications

• Reassurance for Surveillance: The high NPV of endoscopic findings suggests that CDH1 carriers with no visible mucosal abnormalities can be safely managed with continued endoscopic surveillance rather than immediate prophylactic gastrectomy.
• Surgical Indication: The presence of specific "worrisome" findings (masses, thickened folds) combined with positive biopsies warrants a strong discussion regarding total gastrectomy, as these features are highly specific for advanced pathology.
• Limitations of Current Markers: While abnormalities increase risk, their modest PPV indicates that a positive finding does not guarantee advanced cancer; many carriers with these findings still have localized (T1a) disease.
• Future Directions: The study highlights the need for long-term surveillance data and the exploration of adjunctive tools (molecular markers, immune microenvironment analysis, AI) to further refine risk stratification and reduce unnecessary surgeries.

Conclusion: The GASTRIC consortium data supports a risk-stratified management algorithm where the absence of endoscopic abnormalities is reassuring, while the presence of specific mucosal lesions (especially masses and thickened folds) should trigger a discussion of surgery, acknowledging that these findings alone do not definitively predict advanced disease.